Matthew P Banegas1, Donna R Rivera2, Maureen C O'Keeffe-Rosetti1, Nikki M Carroll3, Pamala A Pawloski4, David C Tabano3,5, Mara M Epstein6,7, Kai Yeung8, Mark C Hornbrook1, Christine Lu9,10, Debra P Ritzwoller3. 1. Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. 2. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. 3. Kaiser Permanente Colorado Institute for Health Research, Denver, Colorado. 4. HealthPartners Institute, Bloomington, Minnesota. 5. Denver Public Health, Denver, Colorado. 6. Meyers Primary Care Institute, Worcester, Massachusetts. 7. University of Massachusetts Medical School, Worcester, Massachusetts. 8. Kaiser Permanente Washington Health Research Institute, Seattle, Washington. 9. Harvard Medical School, Boston, Massachusetts; and. 10. Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Abstract
BACKGROUND: Oral tyrosine kinase inhibitors (TKIs) have been the standard of care for chronic myeloid leukemia (CML) since 2001. However, few studies have evaluated changes in the treatment landscape of CML over time. This study assessed the long-term treatment patterns of oral anticancer therapies among patients with CML. METHODS: This retrospective cohort study included patients newly diagnosed with CML between January 1, 2000, and December 31, 2016, from 10 integrated healthcare systems. The proportion of patients treated with 5 FDA-approved oral TKI agents-bosutinib, dasatinib, imatinib, nilotinib, and ponatinib-in the 12 months after diagnosis were measured, overall and by year, between 2000 and 2017. We assessed the use of each oral agent through the fourth-line setting. Multivariable logistic regression estimated the odds of receiving any oral agent, adjusting for sociodemographic and clinical characteristics. RESULTS: Among 853 patients with CML, 81% received an oral agent between 2000 and 2017. Use of non-oral therapies decreased from 100% in 2000 to 5% in 2005, coinciding with imatinib uptake from 65% in 2001 to 98% in 2005. Approximately 28% of patients switched to a second-line agent, 9% switched to a third-line agent, and 2% switched to a fourth-line agent. Adjusted analysis showed that age at diagnosis, year of diagnosis, and comorbidity burden were statistically significantly associated with odds of receiving an oral agent. CONCLUSIONS: A dramatic shift was seen in CML treatments away from traditional, nonoral chemotherapy toward use of novel oral TKIs between 2000 and 2017. As the costs of oral anticancer agents reach new highs, studies assessing the long-term health and financial outcomes among patients with CML are warranted.
BACKGROUND: Oral tyrosine kinase inhibitors (TKIs) have been the standard of care for chronic myeloid leukemia (CML) since 2001. However, few studies have evaluated changes in the treatment landscape of CML over time. This study assessed the long-term treatment patterns of oral anticancer therapies among patients with CML. METHODS: This retrospective cohort study included patients newly diagnosed with CML between January 1, 2000, and December 31, 2016, from 10 integrated healthcare systems. The proportion of patients treated with 5 FDA-approved oral TKI agents-bosutinib, dasatinib, imatinib, nilotinib, and ponatinib-in the 12 months after diagnosis were measured, overall and by year, between 2000 and 2017. We assessed the use of each oral agent through the fourth-line setting. Multivariable logistic regression estimated the odds of receiving any oral agent, adjusting for sociodemographic and clinical characteristics. RESULTS: Among 853 patients with CML, 81% received an oral agent between 2000 and 2017. Use of non-oral therapies decreased from 100% in 2000 to 5% in 2005, coinciding with imatinib uptake from 65% in 2001 to 98% in 2005. Approximately 28% of patients switched to a second-line agent, 9% switched to a third-line agent, and 2% switched to a fourth-line agent. Adjusted analysis showed that age at diagnosis, year of diagnosis, and comorbidity burden were statistically significantly associated with odds of receiving an oral agent. CONCLUSIONS: A dramatic shift was seen in CML treatments away from traditional, nonoral chemotherapy toward use of novel oral TKIs between 2000 and 2017. As the costs of oral anticancer agents reach new highs, studies assessing the long-term health and financial outcomes among patients with CML are warranted.
Authors: Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Mark C Hornbrook; Gene Hart; Jennifer L Ellis; Donald J Bachman; Gary Ansell; Sarah M Greene; Edward H Wagner; Roy Pardee; Mark M Schmidt; Ann Geiger; Amy L Butani; Terry Field; Hassan Fouayzi; Irina Miroshnik; Liyan Liu; Robert Diseker; Karen Wells; Rick Krajenta; Lois Lamerato; Christine Neslund Dudas Journal: J Natl Cancer Inst Monogr Date: 2005
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Bradley C Martin; Elizabeth K Wiley-Exley; Shirley Richards; Marisa E Domino; Timothy S Carey; Betsy Lynn Sleath Journal: Ann Pharmacother Date: 2009-01-06 Impact factor: 3.154
Authors: Jennifer J Wilkes; Gary H Lyman; David R Doody; Shasank Chennupati; Laura K Becker; Pamela E Morin; Lena E Winestone; Henry J Henk; Eric J Chow Journal: JCO Oncol Pract Date: 2020-08-21
Authors: Rory M Shallis; Rong Wang; Jan P Bewersdorf; Amer M Zeidan; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Xiaomei Ma Journal: Ther Adv Hematol Date: 2021-11-30
Authors: Aman Opneja; Gino Cioffi; Asrar Alahmadi; Nelroy Jones; Tin-Yun Tang; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Ankit Mangla; Jill Barnholtz-Sloan; Richard T Lee Journal: Cancer Med Date: 2021-05-31 Impact factor: 4.711